Amgen Inc. (formerly Applied Molecular Genetics Inc.) is one of the world’s largest independent biotechnology companies established at Thousand Oaks, California, in 1980.
| Molecule | Target | Phase | Indication | NCT Number | Mol Type |
|---|---|---|---|---|---|
| Veliparib / ABT 888 | PARP | III | Metastatic Breast Cancer | NCT02163694 | Small Molecule |
| III | Ovarian Cancer | NCT02470585 | |||
| III | Non-Small Cell Lung Cancer | NCT02106546 | |||
| Venclexta™ / Venetoclax / ABT 199 / GDC-0199 | Bcl-2 | III | Multiple Myeloma | NCT03539744 | Small Molecule |
| II | Waldenstrom Macroglobulinemia | NCT02677324 | |||
| Telisotuzumab vedotin / ABBV-399 | cMet | II | Non Small Cell Lung Cancer | NCT03539536 | Antibody Drug Conjugate |
| I | Advanced Solid Tumors Cancer | NCT03311477 | |||
| Mirzotamab / clezutoclax / ABBV-155 | CD275 | I | Advanced Solid Tumors | NCT03595059 | Antibody Drug Conjugate |
| ABBV-621 | TRAIL | I | Advanced Solid Tumors Cancer | NCT03082209 | Fusion Protein |
| Hematologic Malignancies | |||||
| CCW702 | CD3-PSMA | I | Prostatic Cancer (mCRPC) | NCT04077021 | Bispecific Antibody |
| CLBR001 + SWI019 * | CD19 | I | R/R B-cell Lymphomas | NCT04450069 | CAR-T + |
| Diffuse Large B Cell Lymphoma | Monoclonal Antibody | ||||
| ABBV-011 | Undisclosed | I | R/R Small Cell Lung Cancer | NCT03639194 | Antibody Drug Conjugate |
| ABBV-151 | GARP- TGF-β1 | I | Advanced Solid Tumors Cancer | NCT03821935 | Monoclonal Antibody |
| ABBV-155 | Undisclosed | I | Small cell lung cancer | NCT03595059 | Antibody Drug Conjugate |
| Non-Small cell lung cancer | |||||
| Budigalimab /ABBV-181 | PD-1 | I | Advanced Solid Tumors | NCT03000257 | Monoclonal Antibody |
| ABBV-184 | Survivin, CD3 | I | Acute Myeloid Leukemia (AML) | NCT04272203 | Bispecific Antibody |
| Non Small Cell Lung Cancer | |||||
| ABBV-368 | OX40 | I | Advanced Solid Tumors | NCT03071757 | Monoclonal Antibody |
| ABBV-467 | MCL1 | I | R/R Multiple Myeloma | NCT04178902 | Small Molecule |
| ABBV-621 | TRAIL-R1 | I | Advanced Solid Tumors | NCT03082209 | Fusion Protein |
| Hematologic Malignancies | |||||
| Cofetuzumab Pelidotin/ ABBV-647 | PTK7 | I | Non-Small Cell Lung Cancer | NCT04189614 | Antibody Drug Conjugate |
| ABBV-744 | BET | I | Acute Myeloid Leukemia | NCT03360006 | Small Molecule |
| ABBV-927 | CD40 | I | Advanced Solid Tumors | NCT02988960 | Monoclonal Antibody |
Amgen Active Oncology Pipeline Drug Description
- Sotorasib (formerly AMG 510) targets a specific mutation, G12C, in the protein KRAS which is responsible for various forms of cancer.
- AMG 199 is a half-life extended (HLE) anti-MUC17 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of gastric and gastroesophageal junction cancer.
- AMG 256 (anti-PD-1 x IL21 mutein) is a targeted IL-21 receptor agonist designed to selectively turn on the Interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells. It is being investigated for the treatment of solid tumors.
- AMG 330 is an anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of acute myeloid leukemia.
- AMG 404 is a human anti-programmed cell death-1(PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules.
- AMG 427 is a half-life extended (HLE) anti-fms-like tyrosine kinase 3 (FLT3) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of acute myeloid leukemia.
- AMG 506 is a multi-specific FAP x 4-1BB-targeting DARPin® biologic under investigation as a treatment for solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules.
- AMG 506 (also known as MP0310) is being developed in collaboration with Molecular Partners AG.
- AMG 509 (STEAP1 XmAb® antibody) is a bivalent T-cell engager and is designed using XmAb® 2+1 technology. It is being investigated for the treatment of prostate cancer.
- AMG 673 is a half-life extended (HLE) anti-CD33 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of acute myeloid leukemia.
- Pavurutamab (pending INN for AMG 701) is a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of multiple myeloma.
- AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of small-cell lung cancer.
- AMG 910 is a half-life extended (HLE) anti-CLDN18.2 x anti-CD3 BiTE® (bispecific T cell engager) construct. It is being investigated for the treatment of gastric and gastroesophageal junction cancer.
Page 2 of 2
